judge smith, n., re bartram v. glaxosmithkline inc., 12-03[1][1]

17
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

Upload: macleans-magazine

Post on 30-Oct-2014

88.289 views

Category:

Documents


1 download

TRANSCRIPT

Page 1: Judge Smith, N., Re Bartram v. GlaxoSmithKline Inc., 12-03[1][1]

!"#$%&#'()*&+&#,-(*$#-.#/*!$!'%#,-0(+/!1#

!"#$#"%&'( !"#$#"%&'(&)*"+,-%.$/0*.12&314(5(( )*+)(,!-!(+.*/(

0$#1'()*+)+)*2(

0%341#'(-*.+//+(

516"7#89'(:$&3%;<18(

,1#=11&'(

+234#/3565378#39:#!9;3968##

<=#425#+>6425#39:#0?6?@36?>9#AB35:?398#.3?64#A?<C>98##

39:#642#C3?:#.3?64#A?<C>9#

>?$"&#"@@7(

A&B(

AD3E>'7?64FD?92#!9GH#39:#AD3E>'7?64FD?92#(F#0?7?62:#

01@1&B$&#7(

,1@%81'(CD1(E%&%;8$F?1(G8H(I;7#"31(JH(-K"#D(

*23C>9C#;>5#IB:@7296#

!%;&71?(@%8(>?$"&#"@@7'( 0HGH(5%71&F186L(MH!H(

!%;&71?(@%8(01@1&B$&#7'( NHNHIHOH(G3J$K$8$L(

CHIH(N$?7DL(5H!H(-;##%&(

>?$31($&B(0$#1(%@(C8"$?PE1$8"&6'( :$&3%;<18L(,H!H(

Q3#%F18(+L()L()*+)(

>?$31($&B(0$#1(%@(I;B6K1&#'( :$&3%;<18L(,H!H(

0131KF18(2L()*+)(

( (

Page 2: Judge Smith, N., Re Bartram v. GlaxoSmithKline Inc., 12-03[1][1]

!"#$#"%&'(&)*"+,-%.$/0*.12&314(& 5"62&7&

R+S CD1(T?$"&#"@@7(7114(318#"@"3$#"%&(%@($(3?$77($3#"%&($6$"&7#(#D1(K$&;@$3#;818(%@(

$&($&#"B1T8177$&#(B8;6(#D$#("7($??161B(#%(D$<1(3$;71B(F"8#D(B1@13#7("&(3D"?B81&(=D%71(

K%#D187(;71B("#(=D"?1(T816&$&#H(CD19(7$9(#D1(B1@1&B$&#(4&1=(%8(%;6D#(#%(D$<1(

4&%=&(%@(#D1(8"74($&B(@$"?1B(#%(T8%<"B1($B1U;$#1($&B(#"K1?9(=$8&"&6(#%(B%3#%87(

T81738"F"&6(#D1(B8;6($&B(#%(#D1(61&18$?(T;F?"3H((

R)S A33%8B"&6(#%(#D1(7#$#1K1&#(%@(3?$"KL(#D1("&@$&#(T?$"&#"@@(G1$D(,$8#8$K(=$7(

F%8&(%&(-1T#1KF18(+/L()**VL(="#D($(<1&#8"3;?$8(71T#$?(B1@13#WW"&(7"KT?1(#18K7L($(D%?1(

"&(D18(D1$8#H(E18(K%#D18L(#D1($B;?#(T?$"&#"@@(X$"#D(O"F7%&L(=$7(@"87#(T81738"F1B(#D1(

$&#"B1T8177$&#(>$Y"?("&(0131KF18L()**)L($&B(3%&#"&;1B(#%(#$41("#(#D8%;6D%;#(D18(

T816&$&39H((

R2S >$Y"?("7(#D1(#8$B1(&$K1(@%8($(B8;6L($?7%(4&%=&($7(T$8%Y1#"&1L(#D$#(F1?%&67(#%(

$(3$#16%89(%@($&#"B1T8177$&#(K1B"3$#"%&7(3$??1B(71?13#"<1(718%#%&"&(81;T#$41(

"&D"F"#%87(Z[--5\7[]H(CD1(B1@1&B$&#(O?$Y%-K"#D^?"&1(\&3H(Z O-^ ](K$&;@$3#;817L(

K$841#7($&B(71??7(>$Y"?(#D8%;6D%;#(!$&$B$H((

R/S \&@%8K$#"%&(7;6617#"&6($&($77%3"$#"%&(F1#=11&(#D1(;71(%@(>$Y"?("&(T816&$&39(

$&B(3$8B"%<$73;?$8(B1@13#7("&(&1=F%8&7(=$7(@"87#(T;F?"7D1B(F9(O-^(7D%8#?9($@#18(

G1$D(,$8#8$K(=$7(F%8&L(F;#(#D1(T?$"&#"@@7($??161(#D$#(O-^(4&1=(%8(%;6D#(#%(D$<1(

4&%=&(%@(#D1(8"74(F1@%81(#D1&H(G7H(O"F7%&(7$97("&($&($@@"B$<"#(#D$#("@(7D1(D$B(F11&(

$=$81(#D$#(#D181(=181($&9(T%77"F?1(3%&71U;1&317(#%(D18(3D"?B(@8%K(#$4"&6(>$Y"?L(7D1(

=%;?B(D$<1(#$41&($(B"@@181&#($&#"WB1T8177$&#(%8(&%&1($#($??H(

RVS CD1(T?$"&#"@@7($74(#D$#(G7H(O"F7%&(F1($TT%"&#1B(81T8171&#$#"<1(T?$"&#"@@(%&(

F1D$?@(%@($(3?$77(B1@"&1B($7'(

$&9(T187%&("&(!$&$B$L(F%8&(="#D(3$8B"%<$73;?$8(B1@13#7L(#%(=%K1&(=D%(

"&617#1B(>$Y"?(=D"?1(T816&$&#L($&B(#D1(K%#D187(%@(#D%71(T187%&7H(

R_S >$Y"?(=$7(@"87#($TT8%<1B(@%8(;71("&(!$&$B$("&(+``2L($&B("7(3;881&#?9($TT8%<1B(

@%8(#81$#K1&#(%@(K$a%8(B1T8177"<1(B"7%8B18L(T$&"3(B"7%8B18L(7%3"$?(TD%F"$P7%3"$?(

$&Y"1#9(B"7%8B18L(%F7177"<1W3%KT;?7"<1(B"7%8B18L(61&18$?"b1B($&Y"1#9(B"7%8B18($&B(

T%7#W#8$;K$#"3(7#8177(B"7%8B18H(

Page 3: Judge Smith, N., Re Bartram v. GlaxoSmithKline Inc., 12-03[1][1]

!"#$#"%&'(&)*"+,-%.$/0*.12&314(& 5"62&8&

RcS CD1(K$&;@$3#;818(%@($(T81738"T#"%&(B8;6("7(81U;"81B(#%(T;F?"7D($(T8%B;3#(

K%&%68$TDH(CD"7("7($(73"1&#"@"3(B%3;K1&#(#D$#(B1738"F17("&(B1#$"?(#D1(T8%T18#"17L(

3?$"K7L("&B"3$#"%&7($&B(3%&B"#"%&7(%@(;71(%@($(B8;6L($7(=1??($7("&@%8K$#"%&(#D$#(K$9(

F1(81U;"81B(@%8(%T#"K$?L(7$@1($&B(1@@13#"<1(;71H(\#("7(816$8B1B($7([?$F1?"&6[("&(!$&$B$(

$&B("#7(=%8B"&6("7($TT8%<1B($7(T$8#(%@(#D1(T8%3177(F9(=D"3D(E1$?#D(!$&$B$(

$TT8%<17(#D1(B8;6(@%8(7$?1("&(#D"7(3%;&#89H(CD1(T8%B;3#(K%&%68$TD("7($<$"?$F?1(@%8(

81@181&31(F9(B%3#%87(=D%(T81738"F1(#D1(B8;6L($7(=1??($7(F9(K1KF187(%@(#D1(T;F?"3H(\#(

"7(%@#1&(81<"71BL(="#D(E1$?#D(!$&$B$d7($TT8%<$?L(#%(81@?13#(&1=("&@%8K$#"%&H((

R.S CD1(%8"6"&$?(>$Y"?(K%&%68$TD("&3?;B1B(#D1(7#$#1K1&#'(

>816&$&39($&B(e$3#$#"%&'(A?#D%;6D($&"K$?(7#;B"17(D$<1(&%#(7D%=&($&9(

#18$#%61&"3(%8(71?13#"<1(1KF89%#%Y"3(1@@13#7L(#D1(7$@1#9(%@(>Af\e("&(D;K$&(

T816$&$&39(D$7(&%#(F11&(17#$F?"7D1BH(>Af\e(7D%;?B(&%#(F1(;71B(B;8"&6(

T816&$&39(;&?177(#D1(T%#1&#"$?(F1&1@"#(#%(#D1(T$#"1&#(%;#=1"6D7(#D1(T%77"F?1(

8"74(#%(#D1(@1#;7H(

R`S A(81<"71B(K%&%68$TD("77;1B("&(-1T#1KF18L()**/L(81T1$#1B(#D$#(7#$#1K1&#L(

F;#($?7%(81T%8#1B(817T"8$#%89($&B(%#D18(3%KT?"3$#"%&7(81U;"8"&6(T8%?%&61B(

D%7T"#$?"b$#"%&(%@(7%K1(&1=F%8&7(=D%(D$B(F11&(1YT%71B(#%(>$Y"?(B;8"&6(#D1(#D"8B(

#8"K17#18(%@(T816&$&39H(\#($BB1B(#D$#(TD97"3"$&7(#81$#"&6($(T$#"1&#(="#D(>$Y"?(B;8"&6(

#"$?(8"747($&B(F1&1@"#7(%@(

(

R+*S (@"87#(T;F?"7D1B(81@181&31(#%(#D1(4"&B(%@(3%&B"#"%&($#("77;1("&(#D"7(3$71(

3$K1("&($(?1##18("#(71&#(#%(TD97"3"$&7($&B(%#D18(D1$?#D(T8%@177"%&$?7(B$#1B(-1T#1KF18(

)`L()**VWW#=%(=1147($@#18(#D1(F"8#D(%@(#D1("&@$&#(T?$"&#"@@H(CD$#(B%3;K1&#(81@1881B(#%(

T81?"K"&$89(817;?#7(%@($&(1T"B1K"%?%6"3$?(7#;B9(7D%="&6($&("&381$71B("&3"B1&31(%@(

3$8B"%<$73;?$8(B1@13#7L(K%7#(3%KK%&?9(<1&#8"3;?$8(71T#$?(B1@13#7L("&(F$F"17(F%8&(#%(

=%K1&(=D%(D$B(#$41&(>$Y"?(%8(7"K"?$8(B8;67(B;8"&6(#D1(@"87#(#8"K17#18H(CD1(?1##18(

3%&7"B18"&6(#D1(;71(%@(T$8%Y1#"&1("&(=%K1&(=D%($81(T816&$&#(%8(T?$&&"&6(

(

Page 4: Judge Smith, N., Re Bartram v. GlaxoSmithKline Inc., 12-03[1][1]

!"#$#"%&'(&)*"+,-%.$/0*.12&314(& 5"62&9&

R++S X;8#D18("&@%8K$#"%&(=$7(T;F?"7D1B("&(#D1(@%??%="&6(K%&#D7($&B(%&(X1F8;$89(2L(

)**_L(#D1(T8%B;3#(K%&%68$TD(=$7($K1&B1B(#%(81$BL("&(T$8#'(

>816&$&#(N%K1&($&B(J1=F%8&7'(gT"B1K"%?%6"3$?(7#;B"17(%@(T816&$&39(

%;#3%K17(@%??%="&6(K$#18&$?(1YT%7;81(#%($&#"B1T8177$&#7("&(#D1(@"87#(#8"K17#18(

D$<1(81T%8#1B($&("&381$71("&(#D1(8"74(%@(3%&61&"#$?(K$?@%8K$#"%&7L(T$8#"3;?$8?9(

3$8B"%<$73;?$8(Z1H6H(<1&#8"3;?$8($&B($#8"$?(71T#$?(B1@13#7]L($77%3"$#1B(="#D(#D1(

;71(%@(T$8%Y1#"&1H(CD1(B$#$(7;6617#(#D$#(#D1(8"74(%@(D$<"&6($&("&@$&#(="#D($(

3$8B"%<$73;?$8(B1@13#(@%??%="&6(K$#18&$?(T$8%Y1#"&1(1YT%7;81("7(

$TT8%Y"K$#1?9(+PV*(Z)h]L(3%KT$81B(="#D($&(1YT13#1B(8$#1(@%8(7;3D(B1@13#7(%@(

$TT8%Y"K$#1?9(+P+**(Z+(h]("&@$&#7("&(#D1(61&18$?(T%T;?$#"%&H(\&(61&18$?L(71T#$?(

B1@13#7(8$&61(@8%K(#D%71(#D$#($81(79KT#%K$#"3($&B(K$9(81U;"81(7;86189L(#%(

#D%71(#D$#($81($79KT#%K$#"3($&B(K$9(817%?<1(7T%&#$&1%;7?9H(\&@%8K$#"%&(

$F%;#(#D1(71<18"#9(%@(#D1(71T#$?(B1@13#7(81T%8#1B("&(#D1(7#;B"17("7(&%#(

$<$"?$F?1H(

\@($(T$#"1&#(F13%K17(T816&$&#(=D"?1(#$4"&6(>Af\eiL(%8("&#1&B7(#%(F1(F13%K1(

T816&$&#L(7D1(7D%;?B(F1("&@%8K1B(%@(#D1(3;881&#(17#"K$#1(%@("&381$71B(8"74(#%(

#D1(@1#;7(="#D(>Af\ei(%<18(%#D18($&#"B1T8177$&#7H(gY$K"&$#"%&7(%@($BB"#"%&$?(

B$#$F$717L($7(=1??($7(;TB$#1B($&$?9717L(K$9(817;?#("&(3D$&617(#%(#D1(3;881&#(

8"74(17#"K$#17H(!%&7"B18$#"%&(7D%;?B(F1(6"<1&(#%(7="#3D"&6(#%(%#D18(#81$#K1&#(

%T#"%&7L("&3?;B"&6($&%#D18($&#"B1T8177$&#(%8(&%&WTD$8K$31;#"3$?(#81$#K1&#(

7;3D($7(3%6&"#"<1(F1D$<"%8$?(#D18$T9H(C81$#K1&#(="#D(>Af\ei(7D%;?B(%&?9(F1(

3%&#"&;1B(@%8($&("&B"<"B;$?(T$#"1&#L("@(#D1(T%#1&#"$?(F1&1@"#7(%;#=1"6D(#D1(

T%#1&#"$?(8"747 (

\&"#"$#"%&(%@(T$8%Y1#"&1'(X%8(=%K1&(=D%("&#1&B(#%(F13%K1(T816&$&#L(%8($81("&(

#D1"8(@"87#(#8"K17#18(%@(T816&$&39L("&"#"$#"%&(%@(T$8%Y1#"&1(7D%;?B(F1(3%&7"B181B(

%&?9($@#18(%#D18(#81$#K1&#(%T#"%&7(D$<1(F11&(1<$?;$#1BH(

CD$#(7#$#1K1&#(3%&#"&;17(#%($TT1$8("&(#D1(T8%B;3#(K%&%68$TDH(

R+)S \&()**2L(E1$?#D(!$&$B$($TT8%<1B($(3%&#8%??1B(81?1$71(@%8K;?$#"%&(%@(

T$8%Y1#"&1(;&B18(#D1(&$K1(>$Y"?(!5H(CD1(T8%B;3#(K%&%68$TD(%8"6"&$??9(3%&#$"&1B(

#D1(7$K1(7#$#1K1&#($F%;#(;71("&(T816&$&39($7("&(#D1(@"87#(>$Y"?(K%&%68$TD($&B(D$7(

1<%?<1B("&(#D1(7$K1(=$9H(

R+2S CD1(318#"@"3$#"%&(%@($(T8%311B"&6($7($(3?$77($3#"%&("7(6%<18&1B(F9(7H(/(%@(#D1(

6*"77&8#,4229.1:7&;4$L(5-,!(+``_L(3H(V*L(7H(/(Z68;](=D"3D(81$B7'(

/((Z+](CD1(3%;8#(K;7#(318#"@9($(T8%311B"&6($7($(3?$77(T8%311B"&6(%&($&(

$TT?"3$#"%&(;&B18(713#"%&()(%8(2("@($??(%@(#D1(@%??%="&6(81U;"81K1&#7($81(K1#'(

Z$](#D1(T?1$B"&67(B"73?%71($(3$;71(%@($3#"%&j(

ZF](#D181("7($&("B1&#"@"$F?1(3?$77(%@()(%8(K%81(T187%&7j(

Page 5: Judge Smith, N., Re Bartram v. GlaxoSmithKline Inc., 12-03[1][1]

!"#$#"%&'(&)*"+,-%.$/0*.12&314(& 5"62&:&

Z3](#D1(3?$"K7(%@(#D1(3?$77(K1KF187(8$"71(3%KK%&("77;17L(=D1#D18(%8(

&%#(#D%71(3%KK%&("77;17(T81B%K"&$#1(%<18("77;17($@@13#"&6(%&?9(

"&B"<"B;$?(K1KF187j(

ZB]($(3?$77(T8%311B"&6(=%;?B(F1(#D1(T81@18$F?1(T8%31B;81(@%8(#D1(@$"8(

$&B(1@@"3"1&#(817%?;#"%&(%@(#D1(3%KK%&("77;17j(

Z1](#D181("7($(81T8171&#$#"<1(T?$"&#"@@(=D%(

Z"]((=%;?B(@$"8?9($&B($B1U;$#1?9(81T8171&#(#D1("&#1817#7(%@(#D1(

3?$77L(

Z""]((D$7(T8%B;31B($(T?$&(@%8(#D1(T8%311B"&6(#D$#(71#7(%;#($(

=%84$F?1(K1#D%B(%@($B<$&3"&6(#D1(T8%311B"&6(%&(F1D$?@(%@(#D1(

3?$77($&B(%@(&%#"@9"&6(3?$77(K1KF187(%@(#D1(T8%311B"&6L($&B(

Z"""]((B%17(&%#(D$<1L(%&(#D1(3%KK%&("77;17L($&("&#1817#(#D$#("7(

"&(3%&@?"3#(="#D(#D1("&#1817#7(%@(%#D18(3?$77(K1KF187H(

Z)](\&(B1#18K"&"&6(=D1#D18($(3?$77(T8%311B"&6(=%;?B(F1(#D1(T81@18$F?1(

T8%31B;81(@%8(#D1(@$"8($&B(1@@"3"1&#(817%?;#"%&(%@(#D1(3%KK%&("77;17L(#D1(3%;8#(

K;7#(3%&7"B18($??(81?1<$&#(K$##187("&3?;B"&6(#D1(@%??%="&6'(

Z$](=D1#D18(U;17#"%&7(%@(@$3#(%8(?$=(3%KK%&(#%(#D1(K1KF187(%@(#D1(

3?$77(T81B%K"&$#1(%<18($&9(U;17#"%&7($@@13#"&6(%&?9("&B"<"B;$?(

K1KF187j(

ZF](=D1#D18($(7"6&"@"3$&#(&;KF18(%@(#D1(K1KF187(%@(#D1(3?$77(D$<1($(

<$?"B("&#1817#("&("&B"<"B;$??9(3%&#8%??"&6(#D1(T8%713;#"%&(%@(71T$8$#1(

$3#"%&7j(

Z3](=D1#D18(#D1(3?$77(T8%311B"&6(=%;?B("&<%?<1(3?$"K7(#D$#($81(%8(

D$<1(F11&(#D1(7;Fa13#(%@($&9(%#D18(T8%311B"&67j(

ZB](=D1#D18(%#D18(K1$&7(%@(817%?<"&6(#D1(3?$"K7($81(?177(T8$3#"3$?(%8(

?177(1@@"3"1&#j(

Z1](=D1#D18(#D1($BK"&"7#8$#"%&(%@(#D1(3?$77(T8%311B"&6(=%;?B(381$#1(

681$#18(B"@@"3;?#"17(#D$&(#D%71(?"41?9(#%(F1(1YT18"1&31B("@(81?"1@(=181(

7%;6D#(F9(%#D18(K1$&7H(

R+/S CD1(T?$"&#"@@7(7114(%8B187(318#"@9"&6(#D1(@%??%="&6("77;17($7(3%KK%&("77;17'((

$]( 0"B(>$Y"?(3$;71(%8("&381$71(#D1(?"41?"D%%B(%@(F"8#D(B1@13#7k(

F]( \7(>$Y"?(;&@"#(@%8("#7("&#1&B1B(T;8T%71k(

3]( 0"B(#D1(01@1&B$&#L(OeAfQ-G\CE^e\Jg(\J!H(@$"?(#%(=$8&(

3?$77(K1KF187($&BP%8(E1$?#D(!$&$B$(%@(#D1(#8;1(8"74(%@(F"8#D(

B1@13#7(3$;71B(F9(;7"&6(>$Y"?k(

B]( 0"B(#D1(01@1&B$&#L(OeAfQ-G\CE^e\Jg(\J!H(F81$3D($(B;#9(%@(

3$81(#%(3?$77(K1KF187($&B("@(7%L(=D1&($&B(D%=k(

1]( 0%17(#D1(3%&B;3#(%@(01@1&B$&#L(OeAfQ-G\CE^e\Jg(\J!H(

=$88$&#($&($=$8B(%@(T;&"#"<1(B$K$617L($&B("@(7%L(=D$#($K%;&#(

%@(T;&"#"<1(B$K$617(7D%;?B(F1($=$8B1Bk(

Page 6: Judge Smith, N., Re Bartram v. GlaxoSmithKline Inc., 12-03[1][1]

!"#$#"%&'(&)*"+,-%.$/0*.12&314(& 5"62&;&

@]( 0"B(#D1(01@1&B$&#L(OeAfQ-G\CE^e\Jg(\J!Hd7(7%?"3"#$#"%&7L(

%@@187L($B<18#"71K1&#7L(T8%K%#"%&7L(7$?17($&B(7;TT?9(%@(>$Y"?(

@%8(T187%&$?(;71(F9(3?$77(K1KF187(@$??(="#D"&(#D1(K1$&"&6(%@(

[3%&7;K18(#8$&7$3#"%&7[("&(#D1(!<7.1277&8#"4$.427&"19&6,17<%2#&8#,$24$.,1&;4$&R-,!()**/(3H(VcS(Z#D1([,>!>A[]k(

6]( N"#D(817T13#(#%(#D1(7$?17("&(,8"#"7D(!%?;KF"$(%@(>$Y"?(#%(3?$77(

K1KF187(@%8(#D1"8(T187%&$?(;71L(=$7(#D1(01@1&B$&#L(

OeAfQ-G\CE^e\Jg(\J!H($([7;TT?"18[($7(B1@"&1B("&(#D1(

,>!>Ak(

D]( A81(#D1(3?$77(K1KF187([3%&7;K187[($7(B1@"&1B(F9(#D1(

,>!>Ak(

"]( 0"B(#D1(01@1&B$&#L(OeAfQ-G\CE^e\Jg(\J!H(1&6$61("&(

3%&B;3#L($7($??161B("&(#D1(-#$#1K1&#(%@(!?$"KL(#D$#($K%;&#1B(

#%(B131T#"<1($3#7(%8(T8$3#"317(3%&#8$89(#%(#D1(,>!>Ak(

VH( "@(#D1(!%;8#(@"&B7(#D$#(#D1(01@1&B$&#L(OeAfQ-G\CE^e\Jg(\J!Hd(7(

3%&B;3#(=$7(3%&#8$89(#%(#D1(,>!>A(7D%;?B($(K%&1#$89($=$8B(F1(K$B1("&(

@$<%;8(%@(#D1(3?$77($&BL("@(7%L("&(=D$#($K%;&#k(

R+VS CD1(68;(3$K1("&#%(@%831("&(+``VH(\&(-$"1=">&'(&?>2$/&6"1"9"&314(L&)*+)(

,!!A()_*($#(T$8$(2L(#D1(!%;8#(%@(ATT1$?(7$"B(#D$#L($@#18(+c(91$87(%@(1YT18"1&31L(

($&B(6;"B"&6(T8"&3"T?17(Z"&3?;B"&6(#D%71(1YT81771B(

"&(#D1(;4$ H(CD$#(

3?$8"@"3$#"%&(T8%3177(7D%;?B(F9(&%=(D$<1(K$B1(K$&9(318#"@"3$#"%&($TT?"3$#"%&7(?177(

3%KT?1Y($&B(K%81(3$T$F?1(%@(1YT1B"#"%;7(817%?;#"%&H(,;#(%&1(=%;?B(&%#(4&%=(#D$#(

@8%K(#D"7($TT?"3$#"%&L("&(=D"3D(#D1(T$8#"17(D$<1(711&(@"#(#%(T8%<"B1(#D1(3%;8#(="#D(K%81(

#D$&(.*(3$71($;#D%8"#"17(@8%K(#D"7($&B(%#D18(!$&$B"$&(a;8"7B"3#"%&7H(

R+_S J%#="#D7#$&B"&6(#D1(K$77(%@($;#D%8"#9(="#D(=D"3D(\(D$<1(F11&(T8%<"B1BL(#D1(

6;"B"&6(T8"&3"T?17(#D$#($81(F"&B"&6(%&(K1(=181(7;33"&3#?9(7;KK$8"b1B("&(-$"1=">'(

R/S(\&(@,**.4A&'(&B,#,1$,&C6.$>DL()**+(-!!(_.L(R)**+S(2(-H!H5H(+V.($#(T$8$H(+VL(!D"1@(I;7#"31(G3e$3D?"&(B"73;771B(#D811("KT%8#$&#($B<$&#$617(%@(3?$77(

$3#"%&7(%<18($(K;?#"T?"3"#9(%@("&B"<"B;$?(7;"#7'(

+V(HHH(X"87#L(F9($66816$#"&6(7"K"?$8("&B"<"B;$?($3#"%&7L(3?$77($3#"%&7(

718<1(a;B"3"$?(13%&%K9(F9($<%"B"&6(;&&13177$89(B;T?"3$#"%&("&(@$3#W

@"&B"&6($&B(?16$?($&$?97"7H(-13%&BL(F9(B"7#8"F;#"&6(@"Y1B(?"#"6$#"%&(3%7#7(

$K%&67#($(?$861(&;KF18(%@(3?$77(K1KF187L(3?$77($3#"%&7("KT8%<1(

$33177(#%(a;7#"31(F9(K$4"&6(13%&%K"3$?(#D1(T8%713;#"%&(%@(3?$"K7(#D$#(

$&9(%&1(3?$77(K1KF18(=%;?B(@"&B(#%%(3%7#?9(#%(T8%713;#1(%&(D"7(%8(D18(

%=&H(CD"8BL(3?$77($3#"%&7(718<1(1@@"3"1&39($&B(a;7#"31(F9(1&7;8"&6(#D$#(

$3#;$?($&B(T%#1&#"$?(=8%&6B%187(K%B"@9(#D1"8(F1D$<"%;8(#%(#$41(@;??(

$33%;&#(%@(#D1(D$8K(#D19($81(3$;7"&6L(%8(K"6D#(3$;71L(#%(#D1(T;F?"3H(

Page 7: Judge Smith, N., Re Bartram v. GlaxoSmithKline Inc., 12-03[1][1]

!"#$#"%&'(&)*"+,-%.$/0*.12&314(& 5"62&<&

RVS(\&(?"6D#(%@(#D171($B<$&#$617L(G3e$3D?"&(!HIH!H("&7#8;3#1B(3%;8#7(&%#(#%(#$41(

T$8$H(+V]H(

R_S(A#(T$8$H(+_L(7D1(@;8#D18(;&B1873%81B(#D1(?"K"#1B(&$#;81(%@(#D1("&U;"89(%&(

318#"@"3$#"%&'(

R+_S(HHH(#D1(318#"@"3$#"%&(7#$61("7(B13"B1B?9(&%#(K1$&#(#%(F1($(#17#(%@(#D1(

K18"#7(%@(#D1($3#"%&'(711(6*"77&8#,4229.1:7&;4$5&EFFG%8B18(318#"@9"&6($(3?$77(T8%311B"&6("7(&%#($(B1#18K"&$#"%&(%@(#D1(K18"#7(

&6"H<$,&'(&3%H2#."*&B,I"44,&J$9((Z+``c]L(

318#"@"3$#"%&(7#$61(@%3;717(%&(#D1(@%8K(%@(#D1($3#"%&H(CD1(U;17#"%&($#(

#D1(318#"@"3$#"%&(7#$61("7(&%#(=D1#D18(#D1(3?$"K("7(?"41?9(#%(7;3311BL(F;#(

=D1#D18(#D1(7;"#("7($TT8%T8"$#1?9(T8%713;#1B($7($(3?$77($3#"%&(HHH(

RcS(A?#D%;6D(#D1(318#"@"3$#"%&(7#$61(B%17(&%#(1&#$"?($(#17#(%@(#D1(K18"#7(%@($&(

$3#"%&L(#D1(81T8171&#$#"<1(T?$"&#"@@(K;7#(7#"??(17#$F?"7D($&(1<"B1&#"$89(F$7"7(@%8(

#D1(318#"@"3$#"%&(81U;"81K1&#7(T8%<"B1B("&(#D1(;4$L(%#D18(#D$&(#D1(81U;"81K1&#(#D$#(#D1(T?1$B"&67(B"73?%71($(3$;71(%@($3#"%&'(@,**.4AL(7<H#"L($#(T$8$H()Vj(K#12=2.1&'(&)212#"*&L,$,#7&,M&6"1"9"&J$9(L()**V(,!!A(V/*($#(T$8$H()VL(/_(,H!HeH5H(Z/#D]()2/H(RHHHS(

R.S(A?#D%;6D(#D1(B1#18K"&$#"%&(%@(3%KK%&("77;17(%@#1&(T8%<17(3%&#1&#"%;7L(

#D19(&11B(&%#(F1(B1#18K"&$#"<1(%@(?"$F"?"#9(@%8(318#"@"3$#"%&H(CD1(817%?;#"%&(%@($(

7"&6?1(3%KK%&("77;1(B%17(&%#(D$<1(#%(T8%<"B1($(7;@@"3"1&#(F$7"7(@%8(81?"1@H(X%8(

(6"%HI2**&'(&N*2+="$$&6,#H(&Z+``c]L(//(,H!HeH5H(Z2B](2/2($#(T$8$H(V2L(`.(,H!HAH!H())(Z!HAH]L(H2#&!;KK"&6(IHAHL(@%8(#D1(!%;8#H(

R`S(\&($BB"#"%&L(3%KK%&$?"#9(7D%;?B(F1($TT8%$3D1B(T;8T%7"<1?9L("&(?"6D#(%@(#D1(

;&B18?9"&6(U;17#"%&(%@(=D1#D18(3?$77(T8%311B"&67(="??($<%"B(B;T?"3$#"%&(%@(

@$3#W@"&B"&6(%8(?16$?($&$?97"7'(?27$2#1&6"1"9."1&-/,HH.1:&621$#27&314(&'(&O<$$,1L()**+(-!!(/_($#(T$8$H(2`L(R)**+S()(-H!H5H(V2/L(H2#(G3e$3D?"&(!HIH!H((

R+cS CD1("77;17("&(-$"1=">(=181(<189(7"K"?$8(#%(#D%71("&(#D"7(3$71H(CD1(T?$"&#"@@("&(

-$"1=">($??161B(#D$#(D%8K%&1(#D18$T9(B8;67(T81738"F1B(#%(=%K1&(#%(#81$#(#D1(

79KT#%K7(%@(K1&%T$;71(3$;71B(F81$7#(3$&318H(CD"7(3$71(B"@@187("&(#D$#(>$Y"?(=$7(

&%#(T81738"F1B(%&?9(#%(=%K1&L(K;3D(?177(%&?9(#%(T816&$&#(=%K1&L(7%(#D1($??161B(

B$&618($TT?"17(%&?9(#%($(7K$??(716K1&#(%@(>$Y"? H(CD"7(3$71($?7%($??1617($(

H(

\&a;8"17(B"73%<181B($#(%8(7D%8#?9($@#18(F"8#D($81($??161B(#%(F1(81?$#1B(#%(;71(%@(>$Y"?("&(

#D1(@"87#(#8"K17#18(%@(T816&$&39H(

Page 8: Judge Smith, N., Re Bartram v. GlaxoSmithKline Inc., 12-03[1][1]

!"#$#"%&'(&)*"+,-%.$/0*.12&314(& 5"62&=&

,3BC2#>;#1G6?>9#

R+.S CD1(@"87#(81U;"81K1&#(@%8(318#"@"3$#"%&L(71#(%;#("&(7H(/Z+]Z$](%@(#D1(68;L("7(#D$#(

#D1(T?1$B"&67(B"73?%71($(3$;71(%@($3#"%&H(CD1(7#$#1K1&#(%@(3?$"KL(=D"3D(=$7(@"?1B(

;&B18(#D1(@%8K18(5;?17(%@(!%;8#L($??1617'(

)+H( (A7($(817;?#(%@(#D1(#18$#%61&1#"3(1@@13#(%@(>$Y"?L("#(=$7("&D181&#?9(

B$&618%;7(=D1&(#$41&(F9(T816&$&#(=%K1&H(

))H( CD1(01@1&B$&#7($#($??(K$#18"$?(#"K17(%=1B($(B;#9(%@(3$81(#%(#D1(

>?$"&#"@@7(#%'(

$H( 1&7;81(#D$#(>$Y"?(=$7(@"#(@%8("#7("&#1&B1B(%8(81$7%&$F?9(

@%81711$F?1(;71j

FH( 3%&B;3#($TT8%T8"$#1(#17#"&6(#%(B1#18K"&1(=D1#D18($&B(#%(=D$#(

1Y#1&#("&617#"%&(%@(>$Y"?(T%71B(718"%;7(D1$?#D(8"747(#%(T816&$&#(

=%K1&L("&3?;B"&6(#D1(8"74(%@(718"%;7($B<1871(3%KT?"3$#"%&7(@%8(

&1=F%8&(3D"?B81&(%@(K%#D187(=D%("&617#(>$Y"?(B;8"&6(

T816&$&39j($&B

3H( =$8&(#D1(>?$"&#"@@L(X$"#D(O"F7%&($&B(D18(TD97"3"$&7(#D$#(#D1(

"&617#"%&(%@(>$Y"?(3$88"17(#D1(8"74(%@(718"%;7($B<1871(

3%KT?"3$#"%&7(@%8(&1=F%8&(3D"?B81&(%@(K%#D187(=D%("&617#(

>$Y"?(B;8"&6(T816&$&39H

)2H( CD1(01@1&B$&#7(&16?"61&#?9(F81$3D1B(#D1"8(B;#9(%@(3$81L(T$8#"3;?$87(%@(

=D"3D($81(71#(%;#("&(#D1(@%??%="&6(T$8$68$TDH(

R+`S CD1(@%??%="&6(T$8$68$TD(%@(#D1(7#$#1K1&#(%@(3?$"K(?"7#7(+c(T$8#"3;?$87(%@(

&16?"61&31L("&3?;B"&6(@$"?;81(#%($B1U;$#1?9(#17#(>$Y"?L(@$"?;81(#%(3%&B;3#($B1U;$#1(

@%??%=(;T(7#;B"17L(@$"?;81(#%(T8%<"B1(3%KT?1#1($&B($33;8$#1("&@%8K$#"%&(#%(E1$?#D(

!$&$B$L(@$"?;81(#%(=$8&(TD97"3"$&7($&B(T$#"1&#7(%@(#D1(8"74(%@(3$8B"%<$73;?$8(

3%KT?"3$#"%&7($&B(K"781T8171&#$#"%&(%@(#D1(7#$#1(%@(8171$83D($&B(K1B"3$?(?"#18$#;81H(

R)*S e1$<"&6($7"B1(#D1(U;17#"%&(%@(=D1#D18(#D1(T?$"&#"@@7(="??(F1($F?1(#%(T8%<1($&9(

%8($??(%@(#D%71($??16$#"%&7L(#D181(3$&(F1(&%(B%;F#(#D$#(#D19(7#$#1($(3$;71(%@($3#"%&("&(

&16?"61&31H(\&(@,**.7&'(&O,=&6,#1.1:&6,#H(L(R+``VS(/(-!5(_2/L(#D1(-;T81K1(!%;8#(%@(

!$&$B$(7$"B($#(T$8$()2'(

R)2S#HHH(G1B"3$?(T8%B;3#7($81(%@#1&(B17"6&1B(@%8(F%B"?9("&617#"%&(%8(

"KT?$&#$#"%&L($&B(#D1(8"747(381$#1B(F9(#D1"8("KT8%T18(;71($81(%F<"%;7?9(

7;F7#$&#"$?H(CD1(3%;8#7("&(#D"7(3%;&#89(D$<1(?%&6(813%6&"b1B(#D$#(

K$&;@$3#;8187(%@(T8%B;3#7(#D$#($81("&617#1BL(3%&7;K1B(%8(%#D18="71(T?$31B(

"&(#D1(F%B9L($&B(#D181F9(D$<1($(681$#(3$T$3"#9(#%(3$;71("&a;89(#%(3%&7;K187L(

Page 9: Judge Smith, N., Re Bartram v. GlaxoSmithKline Inc., 12-03[1][1]

!"#$#"%&'(&)*"+,-%.$/0*.12&314(& 5"62&>&

$81(7;Fa13#(#%($(3%8817T%&B"&6?9(D"6D(7#$&B$8B(%@(3$81(;&B18(#D1(?$=(%@(

&16?"61&31H(O"<1&(#D1("&#"K$#1(81?$#"%&7D"T(F1#=11&(K1B"3$?(T8%B;3#7($&B(#D1(

3%&7;K18d7(F%B9L($&B(#D1(817;?#"&6(8"74(381$#1B(#%(#D1(3%&7;K18L(#D181(="??(

$?K%7#($?=$97(F1($(D1$<9(%&;7(%&(K$&;@$3#;8187(%@(K1B"3$?(T8%B;3#7(#%(

T8%<"B1(3?1$8L(3%KT?1#1($&B(3;881&#("&@%8K$#"%&(3%&318&"&6(#D1(B$&6187(

"&D181&#("&(#D1(%8B"&$89(;71(%@(#D1"8(T8%B;3#H(R!"#$#"%&7(%K"##1BHS(

R)+S A?#D%;6D(#D1($??161B(T$8#"3;?$87(%@(&16?"61&31(3%<18($(F8%$B(8$&61(%@(

#D$#("#("KT8%T18?9(3%KF"&17(B"7#"&3#(@%8K7(%@(&16?"61&31("&($(=$9(#D$#(="??(K$41("#(

B"@@"3;?#(#%(B1#18K"&1(D%=(1$3D(3?$"K(81?$#17(#%(#D1(3%KK%&("77;17H(J%#(91#(D$<"&6(

D$B(#D1($B<$&#$61(%@(B"73%<189L(=D"3D(K$9($77"7#("&(&$88%="&6(#D1(3?$"KL(#D1(

T?$"&#"@@7(D$B(&%(3D%"31(F;#(#%(7#$#1(T$8#"3;?$87(#D$#(3$7#($7(="B1($(&1#($7(T%77"F?1H(

R))S !<7.1277&

8#"4$.427&"19&6,17<%2#&8#,$24$.,1&;4$5&-,!()**/L(3H()H(Z!868;](CD1(81?1<$&#(

T8%<"7"%&7(%@(#D$#(?16"7?$#"%&($81'(

/(Z+](\&(#D"7(0"<"7"%&'(

[B131T#"<1($3#(%8(T8$3#"31[(K1$&7L("&(81?$#"%&(#%($(3%&7;K18(#8$&7$3#"%&L(

Z$]($&(%8$?L(=8"##1&L(<"7;$?L(B1738"T#"<1(%8(%#D18(81T8171&#$#"%&(F9($(

7;TT?"18L(%8(

ZF]($&9(3%&B;3#(F9($(7;TT?"18((

#D$#(D$7(#D1(3$T$F"?"#9L(#1&B1&39(%8(1@@13#(%@(B131"<"&6(%8(K"7?1$B"&6($(

3%&7;K18(%8(6;$8$&#%8j(

[81T8171&#$#"%&[("&3?;B17($&9(#18K(%8(@%8K(%@($(3%&#8$3#L(&%#"31(%8(%#D18(

B%3;K1&#(;71B(%8(81?"1B(%&(F9($(7;TT?"18("&(3%&&13#"%&(="#D($(3%&7;K18(

#8$&7$3#"%&H(

Z)](A(B131T#"<1($3#(%8(T8$3#"31(F9($(7;TT?"18(K$9(%33;8(F1@%81L(B;8"&6(%8($@#18(

#D1(3%&7;K18(#8$&7$3#"%&H(

Z2](N"#D%;#(?"K"#"&6(7;F713#"%&(Z+]L(%&1(%8(K%81(%@(#D1(@%??%="&6(3%&7#"#;#17($(

B131T#"<1($3#(%8(T8$3#"31'(

Z$]($(81T8171&#$#"%&(F9($(7;TT?"18(#D$#(6%%B7(%8(718<"317(

Z"](D$<1(7T%&7%87D"TL($TT8%<$?L(T18@%8K$&31(3D$8$3#18"7#"37L(

$33177%8"17L("&681B"1&#7L(U;$&#"#"17L(3%KT%&1&#7L(;717(%8(

F1&1@"#7(#D$#(#D19(B%(&%#(D$<1L(

Z""]($81(%@($(T$8#"3;?$8(7#$&B$8BL(U;$?"#9L(68$B1L(7#9?1(%8(K%B1?("@(

#D19($81(&%#L(

HHH(

Page 10: Judge Smith, N., Re Bartram v. GlaxoSmithKline Inc., 12-03[1][1]

!"#$#"%&'(&)*"+,-%.$/0*.12&314(& 5"62&?@&

R)2S \&(-$"1=">L(#D1(!%;8#(%@(ATT1$?(3%&@"8K1B(#D$#(&%&WB"73?%7;81(%@($(K$#18"$?(

@$3#(3$&(68%;&B($(3$;71(%@($3#"%&(;&B18(#D1(!868;&

318#"@"3$#"%&(%@($(3?$"K($6$"&7#($(B8;6(K$&;@$3#;818H(X%8(#D1(T;8T%717(%@(#D"7("77;1("&(

#D1(318#"@"3$#"%&($TT?"3$#"%&L(\(@"&B(#D"7(3$71(#%(F1("&B"7#"&6;"7D$F?1(@8%K(-$"1=">H(

!:296?;?3<D2#,D3CC#

R)/S -13#"%&(/Z+]ZF](%@(#D1(68;(81U;"817($&("B1&#"@"$F?1(3?$77(%@(#=%(%8(K%81(

T187%&7H(g<"B1&31(T;#(@%8=$8B(F9(#D1(B1@1&B$&#(7D%=7(#D$#(F1#=11&(+``2($&B(

)**`L($?K%7#(7"Y(K"??"%&(>$Y"?(T81738"T#"%&7(=181(=8"##1&(@%8(=%K1&(%@(3D"?BWF1$8"&6(

$61H(Q&1(7#;B9(D$7("B1&#"@"1B()*($B<1871(3$8B"%<$73;?$8(1@@13#7("&(&1=F%8&7(=D%(

D$B(F11&(1YT%71B(#%(>$Y"?("&(;#18%H(A(7"K"?$8(3?$77($3#"%&(D$7(F11&(T8%T%71B("&(

-$74$#3D1=$&(F;#("7(&%#(T8%311B"&6H(!%;&71?("&(#D$#(3$71(B1T%717(#D$#(D"7(%@@"31(

=$7(3%&#$3#1B(F9(/)(=%K1&(=D%(=181(T%#1&#"$?(3?$77(K1KF187H(

R)VS !%;&71?(@%8(#D1(B1@1&B$&#($86;17(#D$#(#D1(3?$77(T8%T%71B(=%;?B("&3?;B1(

"&B"<"B;$?7(=D%(;71B(>$Y"?(%<18(#%%(?%&6($(T18"%BL(B;8"&6(=D"3D(#D1(7#$#1(%@(

4&%=?1B61($&B(#D1(7#$&B$8B(%@(3$81(=181(1<%?<"&6H(A(7"K"?$8($86;K1&#(=$7(81a13#1B(

"&(-$"1=">'(

R_*S(N91#D(7;FK"#7(#D$#(#D1()cW91$8(3?$77(T18"%B("7(;&K$&$61$F?1("&(#D1(

3%&#1Y#(%@(#D1(3D$&6"&6(73"1&#"@"3(4&%=?1B61(816$8B"&6(#D1(8"747(%@(D%8K%&1(

#D18$T9H(N91#D(3%&#1&B7(#D$#(#D181("7(&%(3%KK%&$?"#9(F13$;71("#7(B;#9(%@(

3$81(K;7#(F1($771771B($#($(7T13"@"3(T18"%B(%@(#"K1H(N91#D(7;FK"#7(#D$#(#D1(

1<%?<"&6(K1B"3$?(4&%=?1B61($&B(#D1(3%&3%K"#$&#(3D$&6"&6(T81738"F"&6(

"&@%8K$#"%&(T813?;B17($(@"&B"&6(%@($(7"&6?1(3%KK%&(7#$&B$8B(%@(3$81(@%8(#D1(

1&#"81()cW91$8(3?$77(T18"%BH(

R_+S(CD181(K$9(=1??(F1(3D$??1&617("&($77177"&6(#D1(B;#9(%@(3$81(Z$&B(#D1(

7#$&B$8B(%@(3$81](%<18(#D1()cW91$8(3?$77(T18"%BH(-"K"?$8(3%&318&7($8%71("&(

P<%*2>L(F;#(#D1(-;T81K1(!%;8#(%@(!$&$B$(3%&3?;B1B(#D$#(#D1(3%KK%&((\#("7(#%%(1$8?9(#%(7$9("&(#D"7(3$71(

=D$#(7D$T1(#D$#($&7=18(K"6D#(#$41L(F;#(%&1(%F<"%;7(T%#1&#"$?(7%?;#"%&(=%;?B(

F1(#D1(B1<1?%TK1&#(%@(7;FW3?$7717(B1@"&1B(F9(81@181&31(#%(#D1(3D$&6"&6(

T8%B;3#(K%&%68$TD7H(\@(#D1(3?$77(T18"%B(T8%<17(#%(F1(#8;?9(;&K$&$61$F?1L("#(

"7(%T1&(#%(#D1(3%;8#(#%(B1318#"@9(#D1($3#"%&H(CD171($81(81@"&1K1&#7(#D$#(3$&(F1(

$BB81771B($7(#D1(?"#"6$#"%&(T8%6817717H(

R)_S \&(#D"7(3$71L( L(

=D1&(>$Y"?(@"87#(=1&#(%&(#D1(K$841#L(#%(B$#1H(CD$#(K$9(&%#(F1(#D1(3?$77(#D$#(

Page 11: Judge Smith, N., Re Bartram v. GlaxoSmithKline Inc., 12-03[1][1]

!"#$#"%&'(&)*"+,-%.$/0*.12&314(& 5"62&??&

;?#"K$#1?9(T8%311B7(#%(#8"$?(%8(#D$#(K$9(F1(7;33177@;?($#(#8"$?H(X%8(1Y$KT?1L(1<1&("@(

#D1(T?$"&#"@@7(T8%<1(#D$#(O-^(@$"?1B(#%(B"73?%71(=D$#("#(4&1=(%8(7D%;?B(D$<1(4&%=&L(

#D1(1<"B1&31(K$9(7D%=($(B$#1(F1@%81(=D"3D(O-^(3%;?B(&%#(81$7%&$F?9(D$<1(D$B(#D1(

38"#"3$?("&@%8K$#"%&($&BP%8($(B$#1($@#18(=D"3D("#(K$B1($B1U;$#1(B"73?%7;81H(-;3D($(

817;?#(=%;?B(&$88%=(#D1(3?$77(T18"%B($&B(B"7U;$?"@9(K$&9(T%#1&#"$?(3?$77(K1KF187L(

T18D$T7(#%(#D1(T%"&#(=D181L($7(#D1(B1@1&B$&#(7;6617#7L(#D1(3?$77(=%;?B(F13%K1(

<$&"7D"&6?9(7K$??H(,;#("&(K9(<"1=("#("7(T81K$#;81(#%(7T13;?$#1(%&(7;3D(K$##187($&B(\(

@"&B(#D$#(%&(#D1(1<"B1&31(&%=(F1@%81(K1L(#D181("7($&("B1&#"@"$F?1(3?$77H(

$42#)5>J>C2:#,>77>9#!CCB2C#

KL#M?:#)3E?D#G3BC2#>5#?9G523C2#642#D?N2D?4>>:#>;#<?564#:2;2G6CO#

R)cS CD1(T$8#"17(D$<1(T;#(@%8=$8B(3%&@?"3#"&6(1YT18#(1<"B1&31(%&(#D1("77;1(%@(

3$;7$#"%&H(CD1(B1@1&B$&#(81?"17(%&(#D1(1<"B1&31(%@(08H(gB=$8B(e$KK18L($(

T1B"$#8"3"$&($&B(K1B"3$?(61&1#"3"7#L(=D%(7$97(#D$#(1<189(=%K$&(D$7($(#D811(T18(31&#(

3D$&31(%@(6"<"&6(F"8#D(#%($(F$F9(="#D($(3%&61&"#$?(K$?@%8K$#"%&H(E1($BB7(#D$#(#D1(

3$;717(%@(7;3D(K$?@%8K$#"%&7($81(B"<1871L(#D$#(&%(7"&6?1($61&#(3$&(3$;71($??(%@(#D1K(

$&B(%&?9($F%;#(%&1(T18(31&#(%@($??(K$a%8(3%&61&"#$?(K$?@%8K$#"%&7($81(3$;71B(F9(

1YT%7;81(#%(3D1K"3$?7L(K1B"3$#"%&7(%8(8$B"$#"%&H(E1(7$97(#D1(3$;7$#"<1(8%?1(%@(>$Y"?L(

"@($&9L(K;7#(F1(B1#18K"&1B(%&($(3$71WF9W3$71(F$7"7H(

R).S CD1(T?$"&#"@@7(81?9(%&(#D1(1<"B1&31(%@($&(1T"B1K"%?%6"7#L(-D"8$(^8$K18L(=D%(

>$Y"?(3$;717(3$8B"%<$73;?$8(F"8#D(B1@13#7H(

R)`S \#("7(&1"#D18(&13177$89(&%8($TT8%T8"$#1(%&($(318#"@"3$#"%&($TT?"3$#"%&(#%(=1"6D(

#D$#( H(\&($&9(3$71L(

7;6617#(#D$#(#D1(;71(%@(>$Y"?(B;8"&6(T816&$&39("7($77%3"$#1B(="#D($#(?1$7#($&(

"&381$71B(8"74(%@(3$8B"%<$73;?$8(B1@13#7("&(&1=F%8&7H(

R2*S (A;#D%8"#"17(7;3D($7(@"##.1:$,1&'(&O,=&6,#1.1:&6,#HHL()***(,!!A(_*VL(

17#$F?"7D(#D1(B"7#"&3#"%&(F1#=11&(61&18$?($&B("&B"<"B;$?(3$;7$#"%&H(\&(#D1(3%&#1Y#(%@(

Page 12: Judge Smith, N., Re Bartram v. GlaxoSmithKline Inc., 12-03[1][1]

!"#$#"%&'(&)*"+,-%.$/0*.12&314(& 5"62&?7&

#D"7(3$71L(#D1(61&18$?(3$;7$#"%&(U;17#"%&("7(=D1#D18(>$Y"?("7(3$T$F?1(%@(3$;7"&6(

3$8B"$3(F"8#D(B1@13#7($&BL("@(7%L(=D"3D(%&17H(CD$#(="??(B1T1&B(%&(1YT18#(1<"B1&31(#D$#(

="??(F1($TT?"3$F?1(#%(#D1(3?$"K(%@($??(3?$77(K1KF187H(

R2+S \@(#D1(T?$"&#"@@7(@$"?(#%(T8%<1(61&18$?(3$;7$#"%&L(#D$#(="??(F1(#D1(1&B(%@(#D1(

K$##18H(\@(#D19(7;3311BL("#(="??(#D1&(F1(;T(#%(1$3D("&B"<"B;$?(T?$"&#"@@(#%(7D%=(#D$#(#D1(

"&a;89(#D$#(%33;881B(=$7(%@($(4"&B(#D$#(3$&(F1(3$;71B(F9(>$Y"?($&B(=$7("&(@$3#(%&1(

#D$#(=%;?B(?"41?9(&%#(D$<1(%33;881B(F;#(@%8(#D1(;71(%@(>$Y"?H(

R2)S \&($&("&B"<"B;$?($3#"%&L($(T?$"&#"@@(T8%F$F?9(3%;?B(&%#(7;3311B(F9(K181?9(

7D%="&6(#D$#(#D1(;71(%@(>$Y"?("&381$71B(#D1(8"74(%@("&a;89H(\&(6*2%21$7&'(&6*2%21$7L(

)*+)(-!!(2)L(#D1(-;T81K1(!%;8#(%@(!$&$B$(81W

#17#("&(T

3$717("&<%?<"&6(K;?#"T?1(&16?"61&#(B1@1&B$&#7(=D181("#("7(&%#(T%77"F?1(#%(T8%<1(=D"3D(

%&1(3$;71B(#D1("&a;89H(E%=1<18L(9.4$"("&(6*2%21$7(K$9(?1$<1(%T1&($&($86;K1&#(#D$#(

B"@@181&#(3%&7"B18$#"%&7($TT?9("&(3$717("&<%?<"&6(K;?#"T?1(T?$"&#"@@7L(7;3D($7(3?$77(

$3#"%&7H(

R//S#CD"7("7(&%#(#%(7$9(#D$#(&1=(7"#;$#"%&7(="??(&%#(8$"71(&1=(3%&7"B18$#"%&7H(\(

?1$<1(@%8($&%#D18(B$9L(@%8(1Y$KT?1L(#D1(731&$8"%(#D$#(K"6D#($8"71("&(K$77(#%Y"3(

#%8#(?"#"6$#"%&(="#D(K;?#"T?1(T?$"&#"@@7L(=D181("#("7(17#$F?"7D1B(7#$#"7#"3$??9(#D$#(#D1(

B1@1&B$&#d7($3#7("&B;31B($&("&a;89(%&(7%K1(K1KF187(%@(#D1(68%;TL(F;#("#("7(

"KT%77"F?1(#%(4&%=(=D"3D(%&17H(

R22S 01T1&B"&6(%&(=D$#(@"&B"&67(#D1(3%;8#(K$417(%&(7%K1(%@(#D1(%#D18(3%KK%&(

"77;17L(1$3D("&B"<"B;$?($B;?#(T?$"&#"@@(K$9($?7%(D$<1(#%(T8%<1(#D$#($(81$7%&$F?1(

T187%&("&(D18(T%7"#"%&L(D$<"&6(F11&("&@%8K1B(%@(#D1(8"74(%@(#$4"&6(>$Y"?($&B(%@(#D1(

3%;&#18<$"?"&6(8"747(%@(3D$&6"&6(%8(B"73%&#"&;"&6(#81$#K1&#L(=%;?B(D$<1(7#%TT1B(

#$4"&6(>$Y"?H(

R2/S (Q&1(7D%;?B(&%#(K"&"K"b1(#D1(B"@@"3;?#"17(1$3D(T?$"&#"@@(K$9(@$31("&(T8%<"&6(

"&B"<"B;$?(3$;7$#"%&L(F;#(#D%71("77;17(="??(F1("881?1<$&#(="#D%;#($(@"&B"&6(%&(61&18$?(

3$;7$#"%&L(=D"3D("7(3?1$8?9($(3%KK%&("77;1H(

Page 13: Judge Smith, N., Re Bartram v. GlaxoSmithKline Inc., 12-03[1][1]

!"#$#"%&'(&)*"+,-%.$/0*.12&314(& 5"62&?8&

R2VS \(=%;?BL(D%=1<18L(&$88%=(#D1(U;17#"%&(#%(=D1#D18(>$Y"?(3$;717(%8("&381$717(

#D1(?"41?"D%%B(%@(3$8B"%<$73;?$8(F"8#D(B1@13#7H(CD$#("7(#D1(#9T1(%@(B1@13#($??161B("&(#D1(

3$71(%@(#D1(T8%T%71B(81T8171&#$#"<1(T?$"&#"@@($&B("7(#D1(%&?9(#9T1(81@1881B(#%("&(#D1(

T8%T%71B(3?$77(B1@"&"#"%&H(

PL#!C#)3E?D#B9;?6#;>5#?6C#?9629:2:#JB5J>C2O#

R2_S CD181("7(&%(1<"B1&31(#D$#(>$Y"?("7(61&18$??9(;&@"#(@%8("#7("&#1&B1B(;71("&(

#81$#"&6(B1T8177"%&($&B(%#D18(T793D"$#8"3(3%&B"#"%&7H(CD"7(3$71(81?$#17(%&?9(#%("#7(;71(

@%8($(7T13"@"3(68%;T(%@(T$#"1&#7H(CD1(U;17#"%&(7D%;?B(K%81(T8%T18?9(F1(TD8$71B($7(

=D1#D18(>$Y"?("7(;&@"#(@%8(;71(B;8"&6(T816&$&39H(

R2cS CD$#("77;1("7("&1Y#8"3$F?9(#"1B(#%(#D1(61&18$?(3$;7$#"%&("77;1H(ND1#D18(>$Y"?("7(

;&@"#(@%8(;71(B;8"&6(T816&$&39(="??(B1T1&B(%&(=D1#D18("#("7(3$T$F?1(%@(3$;7"&6(

3$8B"%<$73;?$8(F"8#D(B1@13#7L(=D"3D(%&17L($&B(#D1(K$6&"#;B1(%@(#D1(8"74H(\@(#D1(

T?$"&#"@@7(T8%<1(#D$#(#D1(8"74(=$7(7%(681$#(#D$#(>$Y"?(7D%;?B(&%#(D$<1(F11&(6"<1&(#%(

$&9(T816&$&#(=%K1&L(7;3D($(@"&B"&6(="??($TT?9(#%($??(3?$77(K1KF187H(Q&(#D1(%#D18(

D$&BL("@(#D1(T?$"&#"@@7($81(%&?9($F?1(#%(T8%<1($(@$"?;81(#%(B"73?%71($(8"74(#D$#(D$B(#%(F1(

F$?$&31B($6$"&7#(%#D18(8"747($&B(F1&1@"#7L("#(="??(F1(&13177$89(@%8(1$3D(3?$77(

K1KF18(#%(T8%<1(#D$#($(81$7%&$F?1(T187%&("&(D18(T%7"#"%&(=%;?B(D$<1(7#%TT1B(

#$4"&6(>$Y"?H(

QL#M?:#A'F#;3?D#6>#R359#GD3CC#727<25C#39:S>5#%23D64#,393:3#>;#

65B2#5?CNO#

R2.S CD1(1771&31(%@(#D"7("77;1("7WW#%(;71($(T%T;?$8(@%8K;?$#"%&WW

(CD1(T?$"&#"@@7(D$<1(T8%B;31B(1<"B1&31(%&(#D"7(

$TT?"3$#"%&(#D$#L($#(7%K1(T%"&#L(O-^(F13$K1($=$81(%@($&B(B"73?%71B("&@%8K$#"%&(#D$#(

$77%3"$#1B(>$Y"?L($#(?1$7#(%&($(7#$#"7#"3$?(F$7"7L(="#D($&("&381$71B("&3"B1&31(%@(

3$8B"%<$73;?$8(B1@13#7H(CD1(U;17#"%&("7(=D1#D18(#D1("&@%8K$#"%&(T;F?"7D1B(F9(O-^($#(

$&9(6"<1&(#"K1(81@?13#1B($??(#D$#("#(4&1=(%8(%;6D#(#%(D$<1(4&%=&L($&B(=D1#D18(#D1(

=$8&"&67("#("77;1B(3%;?B($&B(7D%;?B(D$<1(F11&("77;1B($#($&(1$8?"18(B$#1H(g<"B1&31(

%&(#D%71(T%"&#7("7(?"41?9(#%(F1(?$861?9L("@(&%#(1&#"81?9L(="#D"&(#D1(3%&#8%?(%@(O-^($&B(

=%;?B(%&?9(F13%K1($<$"?$F?1(#%(#D1(T?$"&#"@@7(#D8%;6D(#D1(B"73%<189(T8%3177H(

Page 14: Judge Smith, N., Re Bartram v. GlaxoSmithKline Inc., 12-03[1][1]

!"#$#"%&'(&)*"+,-%.$/0*.12&314(& 5"62&?9&

R2`S CD1(T?$"&#"@@7(81?9("&(T$8#(%&($(#8$&738"T#(%@(#17#"K%&9(6"<1&(F9($(="#&177("&($&(

AK18"3$&(T8%311B"&6(81?$#"&6(#%(#D1(#"K17(=D1&L("&(#D1(%T"&"%&(%@(#D$#(="#&177L(#D1(

B$&618(=$7L(%8(7D%;?B(D$<1(F11&L(4&%=&H(CD1(B1@1&B$&#(%Fa13#7(#%(#D$#(1<"B1&31($7(

D1$87$9($&B(\($6811(#D1(#8$&738"T#($?%&1(=%;?B(&%#(F1($BK"77"F?1($#(#8"$?H(CD$#(B%17(

&%#(&13177$8"?9(K$41(#D1(1<"B1&31("&$BK"77"F?1(%&($(318#"@"3$#"%&($TT?"3$#"%&L(F;#(\(

B%(&%#(&11B(#%(B13"B1(#D1(T%"&#(F13$;71(#D1(1<"B1&31("7(;&&13177$89(@%8(T8171&#(

T;8T%717H(CD1("&@%8K$#"%&(#D$#(O-^("#71?@(K$B1(T;F?"3L(3%KF"&1B(="#D(#D1(@$3#(#D$#("#(

$?%&1(3%&#8%?7(#D1(1<"B1&31(%@(=D$#(1?71("#(K$9(%8(K$9(&%#(D$<1(4&%=&($&B(=D1&L(

3%&7#"#;#17($(7;@@"3"1&#(1<"B1&#"$89(F$7"7($#(#D"7(7#$61(%@(#D1(T8%311B"&67H(

R/*S CD1(B1@1&B$&#(81?"17(%&(#D1(1<"B1&31(%@(#D1(08H(A&#D%&9(-3"$??"L($&(

%F7#1#8"3"$&($&B(69&13%?%6"7#L(=D%(7$97(#D$#(K$&9(T816&$&#(=%K1&(K;7#(F1(#81$#1B(

@%8(B1T8177"%&L($&B(8"74WF1&1@"#(3%&7"B18$#"%&7(%@(=D1#D18(#%(;71(>$Y"?(="??(B1T1&B(

H(

CD$#(K$9(F1(7%L(F;#(#D1(#D817D%?B("77;1(81?$#"&6(#D1($B1U;$39($&B(#"K1?"&177(%@(

"&@%8K$#"%&($&B(=$8&"&67($F%;#(#D1(7$@1#9(%@(>$Y"?(;71(B;8"&6(T816&$&39(="??(F1(#D1(

7$K1(@%8($??(T?$"&#"@@7H(

R/+S A??(T%#1&#"$?(3?$77(K1KF187($&BP%8(#D1"8(#81$#"&6(B%3#%87(D$B(#%(81?9(%&(#D1(

7$K1(T;F?"7D1B(K$#18"$?H(\@(#D181(=$7($(T%"&#($#(=D"3D(B1<1?%T"&6(4&%=?1B61(K$B1(

#D$#(K$#18"$?("&3%KT?1#1L(K"7?1$B"&6(%8("&$B1U;$#1L(1$3D(3?$77(K1KF18(K$9(7#"??(

D$<1(#%(71T$8$#1?9(T8%<1(#D$#(7D1(=$7(T816&$&#($@#18(#D$#(T%"&#($&B(#D$#L("@(@;??9(

"&@%8K1BL(7D1(3%;?B(%8(=%;?B(D$<1(7$@1?9(7#%TT1B(#$4"&6(>$Y"?H(E%=1<18L(#D$#(B%17(

&%#(B"K"&"7D(#D1(3%KK%&$?"#9(%@(#D1(#D817D%?B("77;1H(

TL#M?:#A'F#<523G4#3#:B6=#>;#G352#6>#GD3CC#727<25C#39:8#?;#C>8#R429#39:#

4>RO#

R/)S CD"7("77;1("7(?"&41B(#%(#D1(T81<"%;7(%&17($&BL(B1T1&B"&6(%&(=D$#(@"&B"&67($81(

K$B1(%&(#D1(%#D18("77;17L(#D1($&7=18(K$9(F1(71?@(1<"B1&#H(,;#(@%8(T8171&#(T;8T%717L(

\(@"&B("#(#%(F1(3?1$8?9($(3%KK%&("77;1H(

Page 15: Judge Smith, N., Re Bartram v. GlaxoSmithKline Inc., 12-03[1][1]

!"#$#"%&'(&)*"+,-%.$/0*.12&314(& 5"62&?:&

UL#)B9?6?V2#M373@2C#

R/2S \&(-$"1=">L(#D1(3$71(K$&$61K1&#(a;B61(318#"@"1B($(7"K"?$8(3%KK%&("77;1(

$&B(81?"1B(%&(6/"*%2#7&'(&;LQ&6"1"9"&6,%H"1>L()*+*(,!!A(V_*L(=D181(#D1(

!%;8#(%@(ATT1$?(7$"B'(

R2+S(A?#D%;6D(#D1(;?#"K$#1(B1#18K"&$#"%&(%@(#D1(1&#"#?1K1&#($&B(U;$&#"@"3$#"%&(

%@(T;&"#"<1(B$K$617(K;7#(F1(B1@1881B(;&#"?(#D1(3%&3?;7"%&(%@(#D1("&B"<"B;$?(

#8"$?7L("#(B%17(&%#(@%??%=L("&(K9(%T"&"%&L(#D$#(&%($7T13#(%@(#D1(3?$"K(%@(T;&"#"<1(

B$K$617(7D%;?B(F1(318#"@"1B($7($(3%KK%&("77;1H(\#("7(K9(<"1=(#D$#(#D1(

D"6DWD$&B1B(#%(=$88$&#(T;&"7DK1&#("7(3$T$F?1(%@(F1"&6(B1#18K"&1B($7($(

3%KK%&("77;1($#(#D1(#8"$?("&(#D"7(T8%311B"&6(=D181(#D1(%#D18(3%KK%&("77;17(

="??(F1(B1#18K"&1BH(CD1(@

"7(&%#D"&6("&(#D"7(3$71(#D$#(="??(81U;"81($(3%&7"B18$#"%&(%@(#D1("&B"<"B;$?(

3"83;K7#$&317(%@(#D1(3?$77(K1KF187("&(%8B18(#%(B1#18K"&1(=D1#D18(#D1(

(CD1(;?#"K$#1(B13"7"%&(%@(

=D1#D18(T;&"#"<1(B$K$617(7D%;?B(F1($=$8B1BL($&B(#D1(U;$&#"@"3$#"%&(%@(#D1KL(

3$&(F1(#8"1B($7($(3%KK%&("77;1(@%??%="&6(#D1(3%KT?1#"%&(%@(#D1("&B"<"B;$?(

#8"$?7H(

R//S \($K(7$#"7@"1B(#D$#(#D1(7$K1($TT8%$3D(7D%;?B(F1(@%??%=1B("&(#D"7(3$71($&B(@"&B(

#D1(3?$"K(@%8(T;&"#"<1(B$K$617(#%(F1($(3%KK%&("77;1H(

,D3?7C#B9:25#642#!5A5B#

R/VS CD1(T8%T%71B("77;17(;&B18(#D1(!868;(B1$?(="#D(#D1(7$K1($??161B(

L($7(#D1(3%KK%&("77;1(%@(@$"?;81(#%(

=$8&H(CD1(T?$"&#"@@7(81?9(%&(#D1(!868;(#%(7114($BB"#"%&$?(%8($?#18&$#1(81K1B"17H(\(

$B%T#(=D$#(=$7(7$"B(F9(#D1(3$71(K$&$61K1&#(a;B61("&(-$"1=">&'(&?>2$/&6"1"9"&

314(L&)*++(,!-!(+*Vc'(

R_+S(CD1(T?$"&#"@@($7718#7($(7#$#;#%89(3?$"K(;&B18(#D1(!868;H(CD1(!868;(3%&318&7(3%&B;3#($&B(81T8171&#$#"%&7(=D

F1#=11&($(7;TT?"18($&B($&("&B"<"B;$?(3;7#%K18H(CD1(U;17#"%&(%@(=D1#D18($(

81T8171&#$#"%&("7(B131T#"<1(%8(K"7?1$B"&6(B%17(&%#(81U;"81($&("&B"<"B;$?(

1&U;"89'(?"A2*"%&'(&R,/17,1&S&R,/17,1L()**`(,!-!(.2`($#(T$8$H(2`H(

HHH(

R_/S(\($6811(="#D(#D1(T?$"&#"@@(#D$#(#D1(%Fa13#"<1(&$#;81(%@(#D1(7#$#;#%89(3$;71(%@(

$3#"%&(;&B18(#D1(!868;("7(7;"#1B(@%8(3?$77(#81$#K1&#H(CD1(T$8#"3"T$#"%&(%@("&B"<"B;$?(3?$77(K1KF187("7(&%#(&13177$89(#%(B1#18K"&1(=D1#D18(#D1(

B1@1&B$&#7(D$<1(F81$3D1B(#D1(7#$#;#1H(

Page 16: Judge Smith, N., Re Bartram v. GlaxoSmithKline Inc., 12-03[1][1]

!"#$#"%&'(&)*"+,-%.$/0*.12&314(& 5"62&?;&

)52;253<?D?6=#

R/_S E$<"&6(@%;&B(#D$#(3%KK%&("77;17(1Y"7#L(\($K(81U;"81B(F9(7H(/Z+]ZB](%@(#D1(

68;(#%(B1#18K"&1("@($(3?$77(T8%311B"&6("7(#D1(T81@18$F?1(T8%31B;81H(CD1(U;17#"%&("7(

=D1#D18L("&(#D1(3"83;K7#$&317(%@(#D"7(3$71L($(3?$77($3#"%&(=%;?B(F1(T81@18$F?1($&BL(

"&(T$8#"3;?$8L(=D1#D18("#(=%;?B(F1(T81@18$F?1(#%("&B"<"B;$?(T8%311B"&67H(@,**.4&'(&

B,#,1$,&C6.$>DL(R)**+S(2(-!5(+V.H(CD1(!%;8#(%@(ATT1$?("&(-$"1=">($BB1B'(

R.cS(CD181(3$&(F1(&%(B%;F#(#D$#(#D1("&B"<"B;$?(3?$"K7(="??(@$31(7"6&"@"3$&#(

3D$??1&617(%@(T8%%@H(CD1(K;?#"T?"3"#9(%@(3$;7$#"<1(@$3#%87("&(#D1(B1<1?%TK1&#(%@(

F81$7#(3$&318($&B(#D1(8%?1(%@(?1$8&1B("&#18K1B"$8"17(="??(318#$"&?9(3%KT?"3$#1(

#D1(#8"$?(%@("&B"<"B;$?(3?$"K7H(E%=1<18L(#D181(3$&($?7%(F1(&%(B%;F#(#D$#(#D1(

B1#18K"&$#"%&(%@(#D1(3%KK%&("77;17(="??(K%<1(#D1(?"#"6$#"%&(@%8=$8BL(718<1(

a;B"3"$?(13%&%K9L($&B("KT8%<1($33177(#%(a;7#"31H(

R/cS CD1(3%KK%&("77;17(="??(81U;"81(1Y#1&7"<1(B"73%<189(#%(B1#18K"&1(#D1(7#$#1(%@(

4&%=?1B61($&B(8171$83D($#(#D%71(7$K1(#"K17L($&B(1YT18#(1<"B1&31(%&(#D1(61&18$?(

3$;7$#"%&("77;1H(\(3$&(#D"&4(%@(&%#D"&6(#D$#(=%;?B(F1(?177(1@@"3"1&#L(K%81(3%7#?9($&B(

K%81(?"K"#"&6(%@($33177(#%(a;7#"31(#D$&(81U;"8"&6(1$3D(3?$77(K1KF18(#%(71T$8$#1?9(

%F#$"&($&B($BB;31(#D1(7$K1(1<"B1&31H(O"<1&(#D1(3%KT?1Y"#9($&B(3%7#?"&177(%@(B%"&6(

7%L(\(B%;F#(#D$#(#D1("77;17(8$"71B(3%;?B(F1(?"#"6$#1B("&($&9(T8%31B;81(F;#($(3?$77(

$3#"%&H(

*2J52C29636?V2#)D3?96?;;#

R/.S \($K(7$#"7@"1B(#D$#(G7H(O"F7%&("7($(81T8171&#$#"<1(T?$"&#"@@(=D%(3$&($B1U;$#1?9(

81T8171&#(#D1(3?$77H(\(813%6&"b1(#D$#(D18(3?$"K(K$9(F1(F8%$B18(#D$&(#D$#(%@(7%K1(

3?$77(K1KF187("&(#D$#L($7($(,8"#"7D(!%?;KF"$(817"B1&#L(7D1(3$&($B<$&31($(3?$"K(

;&B18(#D1(!868;H(E%=1<18L(6"<1&(#D1(?$861(%<18?$T("&(=D$#(K;7#(F1(T8%<1B("&(#D$#(

3?$"K($&B("&(#D1(&16?"61&31(3?$"KL(\(711(&%(3%&@?"3#(="#D(%#D18(3?$77(K1KF187H(\@L($7(

#D1(K$##18(T8%311B7L(7;3D($(3%&@?"3#(F13%K17($TT$81&#L(#D1(3%;8#(K$9($TT%"&#($(

713%&B(81T8171&#$#"<1(T?$"&#"@@(#%(81T8171&#(3?$77(K1KF187(%;#7"B1(#D1(T8%<"&31H(

R/`S \($K($?7%(7$#"7@"1B(#D$#(G7H(O"F7%&(D$7(T8%B;31B($(3$71(K$&$61K1&#(T?$&(

#D$#L(=D"?1(7#"??(61&18$?L(B1K%&7#8$#17(T8%T18(3%&7"B18$#"%&(%@(D%=(#D1($3#"%&(3$&(

Page 17: Judge Smith, N., Re Bartram v. GlaxoSmithKline Inc., 12-03[1][1]

!"#$#"%&'(&)*"+,-%.$/0*.12&314(& 5"62&?<&

T8%311BL($&B(#D$#(3$&(F1(K%B"@"1B($7(&13177$89H(CD1(T?$&(7T13"@"3$??9(T8%<"B17(@%8(

@;8#D18(D1$8"&67(#%(B1#18K"&1(7%K1(K$##187("&(681$#18(B1#$"?L(7;3D($7(#D1(#18K7($&B(

K$&&18(%@(6"<"&6(&%#"31(#%(3?$77(K1KF187H(

RV*S CD1(B1@1&B$&#(%Fa13#7(#%(#D1(T8%T%71B(K$&$61K1&#(T?$&L("&(T$8#(F13$;71("#(

@$"?7(#%(@;??9($BB8177(D%=(#D1("&B"<"B;$?(3$;7$#"%&($&$?97"7("7(#%(F1(B1$?#(="#D(@%8(1$3D(

T;#$#"<1(3?$77(K1KF18H(\(B%(&%#(3%&7"B18("#(1"#D18(81$?"7#"3(%8(&13177$89(#%(3%&7"B18(

#D$#("77;1("&($&9(B1#$"?($#(#D"7(7#$61H(CD1("&B"<"B;$?("77;17(="??(&%#(&11B(#%(F1(

$BB81771B($#($??(;&?177(#D1(T?$"&#"@@(7;3311B7(%&(#D1(#8"$?(%@(#D1(3%KK%&("77;17H(

,>9GDBC?>9#

RV+S CD1($TT?"3$#"%&(#%(318#"@9(#D"7(T8%311B"&6($7($(3?$77(T8%311B"&6("7(68$&#1BL(

="#D(G7H(O"F7%&($7(#D1(81T8171&#$#"<1(T?$"&#"@@H(CD1(3?$77(B1@"&"#"%&($&B(3%KK%&(

"77;17(="??(F1($7(71#(%;#("&(#D1(&%#"31(%@($TT?"3$#"%&L(7;Fa13#(#%(#D1(K%B"@"3$#"%&7(\(

D$<1(K$B1("&(T$8$7(2V($&B(2_($F%<1H(

JH(-K"#D(IH (